1. Home
  2. SOR vs RZLT Comparison

SOR vs RZLT Comparison

Compare SOR & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Source Capital Inc.

SOR

Source Capital Inc.

HOLD

Current Price

$47.92

Market Cap

395.9M

Sector

Finance

ML Signal

HOLD

Logo Rezolute Inc. (NV)

RZLT

Rezolute Inc. (NV)

HOLD

Current Price

$3.45

Market Cap

326.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOR
RZLT
Founded
1968
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
395.9M
326.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SOR
RZLT
Price
$47.92
$3.45
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$9.14
AVG Volume (30 Days)
16.2K
5.0M
Earning Date
01-01-0001
02-11-2026
Dividend Yield
7.24%
N/A
EPS Growth
N/A
N/A
EPS
6.50
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$6.41
N/A
Revenue Growth
N/A
N/A
52 Week Low
$36.41
$1.07
52 Week High
$42.75
$11.46

Technical Indicators

Market Signals
Indicator
SOR
RZLT
Relative Strength Index (RSI) 58.92 50.31
Support Level $46.51 $2.69
Resistance Level $48.45 $3.65
Average True Range (ATR) 0.80 0.30
MACD 0.05 0.33
Stochastic Oscillator 90.00 88.69

Price Performance

Historical Comparison
SOR
RZLT

About SOR Source Capital Inc.

Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.

About RZLT Rezolute Inc. (NV)

Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.

Share on Social Networks: